Lilly Alzheimer's med glides out of Leqembi's slipstream with FDA adcomm request

If you thought that Eli Lilly's donanemab could ensure a smooth regulatory flight in the slipstream of Eisai and Biogen, the FDA has other ideas.

The decision to call a last-minute advisory committee meeting last month for the Alzheimer’s disease med came as a surprise to Lilly’s donanemab team. Not for the request to discuss the therapy’s safety and efficacy, but for the timing of it.